VIDEO: Lumify’s positive results attributed to mechanism of action

In this Healio Video Perspective from the Tear Film & Ocular Surface Society meeting, Melissa Toyos, MD, FACS, discusses positive pharmacovigilance data for Lumify for the treatment of ocular redness.

Lumify (brimonidine tartrate ophthalmic solution 0.025%, Bausch + Lomb), an alpha-2 adrenergic receptor agonist, had a low number of adverse events, and rebound redness was low compared with other available products. These results can be attributed to Lumify’s mechanism of action as a vasoconstrictor, according to Toyos.

“When we are constricting the veins, we actually get better redness relief than when you have alpha-1 or mixed alpha-1/alpha-2 constriction, which affects the arteries,” Toyos said.

Published by:

Sources/Disclosures

Collapse

Source:

Doan S, et al. Ocular vasoconstrictors: Does mechanism of action make a difference? Presented at: Tear Film & Ocular Surface Society meeting; Oct. 30-Nov. 2, 2024; Venice, Italy.

Disclosures:
Toyos reports being a speaker, consultant and researcher for Bausch + Lomb and the medical spokesperson for Lumify.

Read more about

This post was originally published on this site